Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE

Key Points

• Deutsche Bank acquired 75,061 shares of Monte Rosa Therapeutics worth approximately $1.82 million, giving it a 0.09% stake. Institutional investors collectively own 79.96% of GLUE.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $28.50 price target, despite Wells Fargo and JPMorgan lowering their targets to $27.
• Monte Rosa reported weaker-than-expected quarterly results, with an EPS loss of $0.43 versus the $0.38 estimate and revenue of $8.97 million versus $12.91 million expected. Insiders have sold 79,603 shares worth $1.73 million over the past 90 days.

Deutsche Bank AG purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 75,061 shares of the company's stock, valued at approximately $1,816,000. Deutsche Bank AG owned about 0.09% of Monte Rosa Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in GLUE. Russell Investments Group Ltd. bought a new position in Monte Rosa Therapeutics during the third quarter worth $32,000. Lazard Asset Management LLC grew its position in Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company's stock worth $48,000 after purchasing an additional 3,262 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Monte Rosa Therapeutics in the 2nd quarter worth $54,000. Seven Fleet Capital Management LP bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth about $63,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Monte Rosa Therapeutics by 88.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,733 shares of the company's stock worth $72,000 after purchasing an additional 4,565 shares during the period. 79.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Weiss Ratings cut Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research report on Tuesday, August 11th. TD Cowen upgraded Monte Rosa Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $28.50.

Insider Activity

In related news, Director Anthony M. Manning sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at approximately $231,100. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jennifer Champoux sold 2,175 shares of the firm's stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00. Following the sale, the chief operating officer owned 62,371 shares in the company, valued at approximately $1,247,420. The trade was a 3.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 79,603 shares of company stock valued at $1,725,081. Insiders own 6.40% of the company's stock.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock opened at $13.38 on Friday. The firm has a market cap of $1.14 billion, a P/E ratio of -7.60 and a beta of 1.59. The firm has a 50 day simple moving average of $19.72 and a 200 day simple moving average of $18.63. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.60 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $8.97 million during the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. On average, sell-side analysts expect that Monte Rosa Therapeutics, Inc. will post -1.32 EPS for the current year.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

Want to see what other hedge funds are holding GLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source